Product Information
ROPINIROLE HCL ER 4 MG TABLET is a generic product labeled by Solco Healthcare US LLC, priced at $0.4617 per EA under NDC 43547055503. Its NADAC has been published 210 times since Sep 28, 2022.
FDA first approved this application on May 11, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
4 mg/1
Manufacturer
Solco Healthcare US LLCNDC
43547055503
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ROPINIROLEApproval Type
Generic (ANDA)
FDA Application
ANDA204413FDA Approved
5/11/2022
TE Code
AB
On Market Since
3/22/2022
Pharmacological Classes
Price Statistics
The NADAC for ROPINIROLE HCL ER 4 MG TABLET has been published 210 times since Sep 28, 2022, and over the history we have for it it has declined 19.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4617 per EA |
|---|---|
| All-time high | $1.0260 (Dec 14, 2022) |
| All-time low | $0.4617 (Sep 23, 2026) |
| 52-week high | $0.8362 |
| 52-week low | $0.4617 |
| Median price | $0.7317 |
| Average price | $0.7296 |
| Largest weekly change | +72.2% (Oct 19, 2022) |
| Weeks tracked | 210 |
| Tracking since | Sep 28, 2022 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 85% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Solco Healthcare US LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ropinirole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonergot Dopamine Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ROPINIROLE HCL ER 4 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ROPINIROLE HCL ER 4 MG TABLET, manufactured by Solco Healthcare US LLC, is $0.4617 per EA (NDC 43547055503), effective Sep 30, 2026.
How has the price of ROPINIROLE HCL ER 4 MG TABLET changed over time?
Over the history we have for it, the NADAC for ROPINIROLE HCL ER 4 MG TABLET has declined 19.6%. It has been tracked across 210 weekly CMS publications since Sep 28, 2022.
What are the highest and lowest recorded NADAC prices for ROPINIROLE HCL ER 4 MG TABLET?
Since Sep 28, 2022, the NADAC for ROPINIROLE HCL ER 4 MG TABLET has ranged from a low of $0.4617 (Sep 23, 2026) to a high of $1.0260 (Dec 14, 2022), with a median of $0.7317 per EA.
Are there cheaper alternatives to ROPINIROLE HCL ER 4 MG TABLET?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ROPINIROLE HCL 4 MG TABLET, is $0.0713 per EA — about 85% below ROPINIROLE HCL ER 4 MG TABLET.
Who manufactures ROPINIROLE HCL ER 4 MG TABLET?
ROPINIROLE HCL ER 4 MG TABLET (NDC 43547055503) is labeled by Solco Healthcare US LLC, and CMS classifies it as a generic product.